Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The production and clinical implications of SARS-CoV-2 antibodies

Qianfang Hu, Xiaoping Cui, Xinzhu Liu, Bin Peng, Jinyue Jiang, Xiaohui Wang, Yan Li, Wenhui Hu, Zhi Ao, Jun Duan, Xue Wang, Linxiao Zhu, Guicheng Wu, Shuliang Guo
doi: https://doi.org/10.1101/2020.04.20.20065953
Qianfang Hu
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoping Cui
2Department of Medical Laboratory, Chongqing Three Gorges Central Hospital, No.165, Xincheng Road, Wanzhou District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinzhu Liu
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Peng
3Department of Health Statistics, School of Public Health and Management, Chongqing Medical University, No.1, Yixueyuan Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinyue Jiang
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaohui Wang
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Li
4Department of Health Management Centre, Chongqing Three Gorges Central Hospital, No.165, Xincheng Road, Wanzhou District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenhui Hu
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi Ao
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Duan
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue Wang
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linxiao Zhu
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guicheng Wu
4Department of Health Management Centre, Chongqing Three Gorges Central Hospital, No.165, Xincheng Road, Wanzhou District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: guosl999@sina.com wuguic@hotmail.com
Shuliang Guo
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: guosl999@sina.com wuguic@hotmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), a novel betacoronavirus, has caused an outburst of pneumonia cases in Wuhan, China. We report the production of specific IgM and IgG antibodies after the infection of SARS-CoV-2 and its implication for the diagnosis, pathology and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge.

Methods Test results for SARS-CoV-2 IgM and IgG antibodies of 221 confirmed COVID-19 patients were retrospectively examined, and their clinical data were collected and analyzed based on various subgroups. SARS-CoV-2 IgM and IgG antibodies were determined with the chemiluminescence method.

Findings The concentration (S/CO) of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, with a median of 17.38 (IQR 4.39-36.4) for IgM and 5.59 (IQR 0.73-13.65) for IgG. Detection rates reached highest on day 16-18 and day 19-21 for IgM and IgG, which were 73.6% and 98.6%, respectively, with significantly higher concentration of IgG in critically ill patients than in those with mild to moderate disease (P=0.027). The concentration of the antibodies on day 16-21 is not correlated with the course or outcome of the disease (Spearman r < 0.20, P > 0.05). Nasopharyngeal swabs revealed positive SARS-CoV-2 RNA in up to 52.7% of recovered patients after discharge, whose IgG proved to be significantly lower than that of those with negative RNA results (P = 0.009). IgG and IgM were tested twice within 14 days after discharge with a 7-day interval, and the second testing of these antibodies displayed a decrease in concentration of 21.2% (IQR, 11.2%,34.48%) for IgG and 23.05% (IQR, −27.96%,46.13%) for IgM, without statistical significance between the patients with re-detectable positive RNA results and those with negative RNA results after discharge. However, those with positive results experienced a count decrease in lymphocyte subsets.

Interpretation The concentration of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, and antibody testing on day 16-21 is associated with increased detection rates, but the antibody concentration does not affect the course and outcome of the infection. Recovering patients with re-detectable positive SARS-CoV-2 RNA displayed lower concentration of IgG, but the downward trend of IgG during recovery indicated its limited duration of protection, and the protective effect of IgG remains to be investigated.

Funding Chongqing Education Board, Chongqing Science and Technology Bureau, Famous teacher project of Chongqing talent plan

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding 1. Chongqing Education Board "new coronavirus infection and prevention" emergency scientific research project (KYYJ202006). 2. Chongqing Science and Technology Bureau "new crown pneumonia epidemic emergency science and technology special" the fourth batch of projects. 3. Famous teacher project of Chongqing talent plan.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding

    1. Chongqing Education Board “new coronavirus infection and prevention” emergency scientific research project (KYYJ202006).

    2. Chongqing Science and Technology Bureau “new crown pneumonia epidemic emergency science and technology special” the fourth batch of projects.

    3. Famous teacher project of Chongqing talent plan

Data Availability

With the permission of the corresponding authors, we can provide participant data without names and identifiers, but not the study protocol, statistical analysis plan, or informed consent form. Data can be provided after the Article is published. Once the data can be made public, the research team will provide an email address for communication. The corresponding authors have the right to decide whether to share the data or not based on the research objectives and plan provided.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 24, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The production and clinical implications of SARS-CoV-2 antibodies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The production and clinical implications of SARS-CoV-2 antibodies
Qianfang Hu, Xiaoping Cui, Xinzhu Liu, Bin Peng, Jinyue Jiang, Xiaohui Wang, Yan Li, Wenhui Hu, Zhi Ao, Jun Duan, Xue Wang, Linxiao Zhu, Guicheng Wu, Shuliang Guo
medRxiv 2020.04.20.20065953; doi: https://doi.org/10.1101/2020.04.20.20065953
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The production and clinical implications of SARS-CoV-2 antibodies
Qianfang Hu, Xiaoping Cui, Xinzhu Liu, Bin Peng, Jinyue Jiang, Xiaohui Wang, Yan Li, Wenhui Hu, Zhi Ao, Jun Duan, Xue Wang, Linxiao Zhu, Guicheng Wu, Shuliang Guo
medRxiv 2020.04.20.20065953; doi: https://doi.org/10.1101/2020.04.20.20065953

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5219)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5823)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (345)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)